Aigen Investment Management LP Makes New Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,767 shares of the company’s stock, valued at approximately $216,000.

Other institutional investors also recently modified their holdings of the company. New York State Common Retirement Fund increased its holdings in Apogee Therapeutics by 8.9% during the 4th quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock valued at $552,000 after purchasing an additional 1,000 shares during the period. Rhumbline Advisers increased its stake in shares of Apogee Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 52,720 shares of the company’s stock valued at $2,388,000 after buying an additional 1,750 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after acquiring an additional 892 shares in the last quarter. SG Americas Securities LLC lifted its stake in Apogee Therapeutics by 22.2% in the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company’s stock worth $448,000 after acquiring an additional 1,796 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Apogee Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock valued at $1,736,000 after acquiring an additional 1,212 shares in the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on APGE shares. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics presently has a consensus rating of “Buy” and an average target price of $91.60.

Insider Activity at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 4,540 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40. Following the sale, the insider now directly owns 258,073 shares of the company’s stock, valued at approximately $12,583,639.48. This represents a 1.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark C. Mckenna acquired 20,000 shares of Apogee Therapeutics stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $49.54 per share, with a total value of $990,800.00. Following the completion of the purchase, the director now owns 20,000 shares in the company, valued at $990,800. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 53,735 shares of company stock valued at $2,247,762 in the last 90 days. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $36.14 on Monday. Apogee Therapeutics, Inc. has a 1 year low of $29.10 and a 1 year high of $72.29. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -14.93 and a beta of 2.46. The company has a 50-day moving average of $38.92 and a 200 day moving average of $46.90.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). On average, equities analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.